奧威控股(01370.HK)：保定熹南與衞健局及醫院訂立終止協議
格隆匯3月3日丨奧威控股(01370.HK)發佈公告，誠如此前披露，在收購熹南投資前，保定熹南醫療管理諮詢有限公司(收購事項完成後為公司間接全資附屬公司)已與河北省保定市容城縣衞生和計劃生育局簽訂了有關容城縣中醫醫院(“醫院”)託管經營的《託管經營容城縣中醫醫院的合作協議書》及與醫院簽訂了有關託管事項的《託管協議書》(統稱“《醫院託管協議書》”)。《醫院託管協議書》規定(其中包括)，倘由於法律法規及相關政策變化而使《醫院託管協議書》與現有法律法規或政策發生衝突，或倘訂約方由於不可抗力因素而無法履行義務時，訂約方應修改或終止《醫院託管協議書》。
公告表示，最近的一項政府政策可能會對公司的醫院管理業務運營產生不利影響。根據容城縣衞生健康局向容城縣中醫醫院發出的文件，為全面提高全縣醫療水平、有效改善民生，為雄安新區的規劃建設提供堅實的醫療衞生服務保障，衞健局要求醫院與其指定的北京醫療衞生部門合作，並終止與保定熹南的《醫院託管協議書》。
公司已徵詢中國法律顧問的法律意見，並獲告知，終止《醫院託管協議書》乃由於法律法規及相關政策的變化所致，且各訂約方持續履行《醫院託管協議書》將與現有法律法規或政策相牴觸。中國法律顧問進一步告知，導致訂約方無法繼續根據《醫院託管協議書》履行職責乃人力不可抗力因素的一種形式。若終止《醫院託管協議書》，經公司初步測算，對全資附屬公司熹南投資無形資產賬面價值計提損失撥備約人民幣1.652億元，有關數據尚未經公司核數師審核。
根據上述政府機構文件並充分考慮中國法律顧問的法律意見後，保定熹南已分別與衞健局及醫院於2020年3月3日訂立終止協議，以達致(i)《醫院託管協議書》的所有權利及義務應立即終止，惟各方仍應按終止協議約定處理善後事宜，及(ii)衞健局承諾，在其管轄範圍內的其他醫療項目的條件相同情況下，保定熹南應享有優先權。公司亦將依託醫療專家團隊積極尋找機會並開展相關醫療業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
